Home » Stocks » Stealth BioTherapeutics

Stealth BioTherapeutics Corp. (MITO)

Stock Price: $1.43 USD -0.04 (-2.72%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 71.20M
Revenue (ttm) 21.09M
Net Income (ttm) -71.73M
Shares Out 49.79M
EPS (ttm) -1.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $1.43
Previous Close $1.47
Change ($) -0.04
Change (%) -2.72%
Day's Open 1.48
Day's Range 1.41 - 1.47
Day's Volume 6,330
52-Week Range 0.90 - 14.41

More Stats

Market Cap 71.20M
Enterprise Value 36.67M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 49.79M
Float n/a
EPS (basic) -2.28
EPS (diluted) -1.04
FCF / Share -1.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 97,916
Short Ratio 1.57
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.38
PB Ratio 6.29
Revenue 21.09M
Operating Income -45.83M
Net Income -71.73M
Free Cash Flow -48.11M
Net Cash 34.53M
Net Cash / Share 0.69
Gross Margin 100.00%
Operating Margin -217.35%
Profit Margin -340.20%
FCF Margin -228.17%
ROA -54.61%
ROE -263.75%
ROIC -184.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 1
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(104.20% upside)
Current: $1.43
Target: 2.92
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit21.09---
Operating Income-45.83-75.28-79.72-61.85
Net Income-71.73-96.71-82.91-61.05
Shares Outstanding37668.4868.4768.17
Earnings Per Share-2.28-16.92-14.52-10.80
Operating Cash Flow-47.98-72.08-69.84-54.02
Capital Expenditures-0.13-0.01-0.16-0.29
Free Cash Flow-48.11-72.09-70.00-54.31
Cash & Equivalents50.7710.864.129.71
Total Debt16.2412264.05-
Net Cash / Debt34.53-111-59.939.71
Book Value17.27-387-291-210
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Stealth BioTherapeutics Corp.
Country United States
Employees 73

Stock Information

Ticker Symbol MITO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MITO
IPO Date February 15, 2019


Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.